Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Generex Biotechnology
So what: Generex first received a delisting notice in 2008 for having a stock price of less than $1.00. Since then, the company has gone through a series of appeals, and a reverse stock split proposal failed in a shareholder vote.
Now what: Generex anticipates its common stock will no longer be traded on Nasdaq as of tomorrow. Starting then, the company anticipates the stock will be found over the counter under the ticker GNBT.OB. This will reduce liquidity for shareholders but doesn’t restrict the company from moving back to Nasdaq if a reverse split agreement can be reached.
Interested in more info on Generex Biotechnology? Add it to your watchlist by clicking here.
